BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30842311)

  • 1. New insights into niclosamide action: autophagy activation in colorectal cancer.
    Newton PT
    Biochem J; 2019 Mar; 476(5):779-781. PubMed ID: 30842311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
    Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
    Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
    Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
    J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
    Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
    Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
    Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
    Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
    Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
    Burock S; Daum S; Keilholz U; Neumann K; Walther W; Stein U
    BMC Cancer; 2018 Mar; 18(1):297. PubMed ID: 29544454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
    Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanisms of niclosamide antitumor activity].
    Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
    Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
    Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
    Cancer Lett; 2017 Mar; 389():41-48. PubMed ID: 28043913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
    Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
    Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
    Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
    BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
    Wang LH; Xu M; Fu LQ; Chen XY; Yang F
    Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.
    Chang X; Zhen X; Liu J; Ren X; Hu Z; Zhou Z; Zhu F; Ding K; Nie J
    Kidney Int; 2017 Sep; 92(3):612-624. PubMed ID: 28318631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
    Cheng X; Xu X; Chen D; Zhao F; Wang W
    Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of aquaporin-5 sensitizes colorectal cancer cells to 5-fluorouracil via inhibition of the Wnt-β-catenin signaling pathway.
    Li Q; Yang T; Li D; Ding F; Bai G; Wang W; Sun H
    Biochem Cell Biol; 2018 Oct; 96(5):572-579. PubMed ID: 29390193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1
    Chen B; Zhang D; Kuai J; Cheng M; Fang X; Li G
    Tumour Biol; 2017 Jun; 39(6):1010428317715155. PubMed ID: 28639895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.